Biobanks Market (2025 - 2030)

Biobanks Market Summary

The global biobanks market size was estimated at USD 81.29 billion in 2024 and is projected to reach USD 126.69 billion by 2030, growing at a CAGR of 7.85% from 2025 to 2030. High investments in the R&D of advanced therapies, such as regenerative medicine, personalized medicine, and cancer genomic studies, are some of the driving factors.

Moreover, the onset of COVID-19 has put biobanks at the forefront of the pandemic control measures, resulting in the organic revenue growth of the market. The COVID-19 outbreak had a major influence on the biobanks industry. Biobanking is important for the diagnosis & production of medicines for a variety of disorders. International initiatives to produce vaccines and other medicines to prevent the spread of the virus have been urgently needed.

The collection, processing, and analysis of patient samples are at the frontline of the COVID-19 crisis. For example, the Health Minister announced EUR 2 million in financing for the National Irish COVID-19 Biobank (NICB) in a July 2021 update from the Government of Ireland. The NICB has become a critical part of Ireland’s COVID-19 pandemic response. According to a February 2021 release, the Sample Collection Database was designed by the SciLifeLab Data Centre in partnership with Biobank Sweden and the research area ‘Biobanks for COVID-19’ of the SciLifeLab & KAW National COVID-19 research program. Furthermore, Tulane University announced a new COVID-19 biobank containing blood & cell samples from survivors in July 2021 to aid researchers in determining why some people heal rapidly while others have long-term effects. As a result, such activities show that the outbreak of the pandemic boosted the demand for biobank services, benefiting the global economy.

The increasing popularity of precision/personalized medicine and genetic testing has been a key driver of the market. Biobanks have been playing a significant role in biomedical research. Over the past few decades, there have been several advances in platforms and tools used in genetic studies. This has led to an increase in demand for biospecimens from clinical labs to develop assays for genetic testing. Collaborations between private and public institutions in biobanking have played a crucial role in market progression.

Digitalization, precision medicine, and virtualization are rapidly changing the biobanking industry through the development of novel methods and concepts of collaborations initiated by public and private organizations. Companies across all fields are partnering with biobanks, which accelerates the market revenue. For instance, in October 2023, UK Biobank partnered with several philanthropists. Through this partnership, UK Biobank will access USD 34.5 million in funding.

An exponential increase in the number of global cases has rendered the significance of biobanks in containing the spread of the virus. High-quality COVID-19 specimens are required and helpful for both research and diagnostic purposes, and biobanks are considered vital repositories for these samples. Thus, biobanks are gaining ground to support clinical research and drug discovery processes to combat this global disaster.

Furthermore, developing countries from the Middle East region are investing in biobanks to advance the medical research domain in the region. For instance, in September 2023, the Crown Prince of Abu Dhabi announced the launch of a biobank to support the requirement of personalized medicine through advanced treatments that utilize human tissues and stem cells in medical research. This research will help treat over 80 diseases and immune system issues. Moreover, it strengthens the position of the UAE in the global biobank market.

Biobanks play a critical role in advancing biomedical research by systematically collecting, storing, and managing biological specimens and associated data. These repositories support a wide range of applications, including drug discovery, genomics, personalized medicine, and public health studies. Below is a list of some of the largest and most influential biobanks operating globally, recognized for their scale, diversity of samples, and research impact.

List of largest biobanks across the globe:

Source:Biobanking.com

Market Concentration & Characteristics

The biobanks market has witnessed significant innovation, from traditional sample storage to incorporating advanced data management, analytics tools, and automation. Integration of omics technologies, such as genomics, and increased collaboration globally have further enhanced research capabilities. These developments accelerate biomedical research and contribute to the evolution of personalized medicine.

The biobanks market is also characterized by a high level of mergers and acquisitions (M&A) activity by the leading players. This is due to several factors, including the desire to gain access to new biobank technologies and talent, the need to consolidate in a rapidly growing market, and its usage in research and development.

The market is also subject to increasing regulatory scrutiny. These regulations dictate the responsible collection, storage, and use of biological samples, emphasizing informed consent, privacy protection, and data security. Compliance is crucial for ensuring the reliability of stored samples, facilitating international collaboration, and addressing emerging ethical considerations related to advancements in technologies such as genomics and data analytics.

Product expansion in the biobanks market involves strategic initiatives to introduce new services and offerings. The key players focus on diversifying sample collections, implementing advanced data management systems, providing specialized services, creating collaborative platforms, integrating omics technologies, adopting automation, and establishing global partnerships.

In the biobanks industry, regional expansion involves biobanking entities strategically broadening their activities beyond current geographic boundaries. Hence, key players undertake several business initiatives, such as geographical expansion, partnerships, and collaboration, to gain a regional customer base.

Product & Services Insights

The services segment dominated the market and accounted for the largest revenue share in 2024 and is anticipated to grow at the fastest CAGR during the forecast period. Governments and research organizations are investing heavily in large-scale genomics and biomarker studies, creating sustained demand for high-quality biospecimen collection, processing, and storage. Additionally, advancements in biobanking technologies, such as automated storage systems, digital sample tracking, and cloud-based data integration, are enhancing the efficiency and scalability of biobank operations. Regulatory support and collaborations between academia, industry, and healthcare institutions further accelerate the adoption of biobanking services.

The product segment is anticipated to grow at a significant CAGR during the forecast period. The growth of this segment is primarily driven by the growing need for advanced storage and preservation equipment to support the rising volume and diversity of biological samples used in research and clinical applications. In February 2023, UK Biobank announced that it made a public dataset from 45,000 Magnetic Resonance Imaging (MRI) scans.

Biospecimen Type Insights

Based on biospecimen type, the global biobanks market has been categorized into human tissues, organs, stem cells, and other biospecimen. The human tissues segment captured the largest revenue share of 36.74% in 2024, owing to a large number of biobanks with facilities to store tissues, easy availability of tissue samples, and availability of advanced technology for storage and retrieval of banked tissues. Growing investment in disease-specific R&D is anticipated to foster the demand for diseased tissue samples, such as lymphoma, myeloma, ovarian leukemia, brain, prostate, colorectal carcinoma, breast, and lung tissues for oncology studies.

In the effort to advance the research on COVID-19 and improve its diagnosis and treatment, the stem cells segment is expected to witness the fastest growth during the forecast period. The number of established stem cell biobanks has been increasing rapidly worldwide. Promising applications of stem cells in regenerative medicine, cell therapy, developmental biology, toxicology, and drug development can be attributed to the rapid increase in the number of stem cell banks. Preservation of cellular characteristics, preventing deterioration & contamination, use in basic & translation research, and potential and current use in clinical applications are factors that significantly contributed to the adoption of stem cell banking.

Biobanks Type Insights

Based on biobanks type, the global market is bifurcated into physical/real biobanks and virtual biobanks. The physical/real biobanks segment dominated the market in 2024 and accounted for the largest revenue share of 75.24%. These biobanks have a well-established network, thereby holding a high revenue share. Rapid progress in the fields of bioinformatics analysis and precision medicine can be attributed to this change in the operating strategy of the biobanks. A large collection of tissue samples from pathological labs, clinical trials, and research projects over the years contributes to the largest share of tissue banks in 2024.

The virtual biobanks segment is expected to witness the fastest CAGR over the forecast period. Virtual biobanks have emerged to address the problems related to the accessibility of biospecimen. Tissue Solutions (Scotland) and Human Focused Testing (Little port) are examples of organizations whose core operating activity involves procurement and distribution of samples as per requirement. The potential to fulfill the need for biospecimens and the ability to trace and obtain rare samples improves with virtual biobanking. Also, easy accessibility associated with virtual biobanks contributes to the lucrative growth of the segment.

Application Insights

Based on application, the biobanks industry is categorized into therapeutics, drug discovery & clinical research, clinical diagnostics, and other applications. In 2024, the therapeutics application segment dominated the market with the largest revenue share of 37.63%. This can be attributed to the ever-increasing demand for advanced therapies for treatment of chronic diseases. The exponential increase in the number of COVID-19 cases across the globe has resulted in an increasing need for development of novel viral therapeutics. Various studies are being conducted to accelerate research in this field.

On the other hand, the clinical diagnostics segment is anticipated to witness a significant growth over the forecast period. Comparison of biospecimen obtained from healthy and diseased individuals advances the clinical diagnosis process, especially for cancer. It helps investigate the treatment response of the patient and identify a new tumor in a patient with a history of cancer.

Regional Insights

North America accounted for the second largest revenue share of the biobanks industry in 2024, owing to the advanced healthcare infrastructure, strong government and private sector funding for genomics and personalized medicine, and a well-established regulatory framework supporting biobanking practices. The presence of large-scale initiatives like the NIH-funded “All of Us” research program and extensive academic and commercial research in genomics fuel demand for biobanking services and products. High awareness and adoption of digital and automated storage solutions further accelerate market growth in the region.

U.S. Biobanks Market Trends

In the U.S., biobank industry’s growth is propelled by major government-led initiatives in precision medicine, increasing investments in cancer and rare disease research, and the presence of prominent research institutions and pharmaceutical companies. Programs like the National Cancer Institute’s biorepositories and increased focus on interoperability of health data are pushing for standardized and scalable biobanking solutions. The country also benefits from a mature digital health ecosystem that supports efficient sample and data management.

Europe Biobanks Market Trends

Europe biobanks industry accounted for the largest revenue share of 39.37% in 2024, owing to the continuous investment in the collection, establishment, and processing of large-scale datasets. Furthermore, countries like the UK, Germany, and France are contributing to the regional market growth by investing in biobank solutions. For instance, in June 2023, The Medicines and Healthcare products Regulatory Agency (MHRA) collaborated with Genomics England to launch its genetic biobank.

The UK biobanks market growth is significantly driven by national-scale programs such as the UK Biobank project, which supports broad research initiatives in public health, genomics, and epidemiology. Strong academic-industry collaboration, government support, and integration of biobanking into NHS-backed health research projects contribute to the robust demand for biobanking infrastructure and data analytics tools. Additionally, policy support around open data sharing fosters innovation and multi-institutional collaboration.

The biobanks market in Germany is influenced by initiatives like the German Biobank Node (GBN) and its integration into the Network of University Medicine (NUM), aimed at centralizing and digitizing biobanking resources. Federal funding through agencies like BMBF supports the development of standardization, quality control, and cross-institutional interoperability, while strong pharmaceutical and diagnostics sectors drive sample demand. Advanced hospital networks and academic research institutions also support market expansion.

Asia Pacific Biobanks Market Trends

The Asia Pacific biobanks industry is expected to witness the fastest CAGR over the forecast period. The growth can be attributed to the investment of developing economies like India, China, and Japan. These countries are actively engaged in developing the biobank market by undertaking several business initiatives to strengthen their market position. For instance, in November 2023, AIG Hospital launched its first biobank in India’s southern region. The biobank will collect over one lakh tissue and blood samples for the upcoming decade.

China biobanks market is rapidly expanding, fueled by national efforts to become a global leader in biomedical research, large-scale population genomics projects, and increasing health data digitization. Government-backed initiatives like the China Kadoorie Biobank and rising investment in biotechnology create significant demand for storage systems, sample prep, and high-throughput sequencing tools. Local manufacturing growth and foreign collaborations further stimulate the product and services landscape.

The biobanks market in Japan benefits from a strong emphasis on aging-related and personalized medicine research. Government-funded efforts such as BioBank Japan support large-scale health data collection, particularly for chronic disease research. Technological innovation, combined with Japan’s high standard of healthcare and research integrity, fosters strong demand for integrated biobanking solutions. Additionally, collaborations with global biopharma companies push demand for standardized and automated systems.

MEA Biobanks Market Trends

The Middle East & Africa region shows growing interest in biobanking due to increasing investments in healthcare infrastructure, precision medicine, and population health research. Countries like the UAE and Qatar are developing national biobank programs, while Africa is seeing rising participation in infectious disease and genomics studies. However, challenges like limited standardization and funding disparities remain, although international collaborations are helping to close gaps and drive adoption.

Saudi Arabia’s biobanks market is expanding as part of its Vision 2030 strategy, which includes a strong focus on healthcare digitization and genomics. The launch of national initiatives such as the Saudi Human Genome Program and investments in biotech parks and research universities are fueling the need for advanced biobanking systems. Strong government backing and a push for personalized healthcare solutions support both infrastructure and product market growth.

The biobanks market in Kuwait is expected to develop in tandem with public health and precision medicine initiatives, with support from the Ministry of Health and regional research collaborations. Focused efforts on chronic disease research, especially diabetes and cardiovascular conditions, are driving demand for sample collection and storage infrastructure. However, the market is still at an early stage and is likely to benefit from partnerships with global biobank technology providers.

Heat Map Analysis

The biobanking market is supported by key players such as Thermo Fisher Scientific Inc., Merck KGaA, Qiagen, Stemcell Technologies, and PromoCell GmbH, each offering specialized products and services. Thermo Fisher dominates with a broad portfolio including cryogenic storage, automated sample handling, and data management systems, making it a comprehensive solutions provider with a global footprint. Merck KGaA focuses on cell culture media, cryopreservation reagents, and biobank-compatible consumables, leveraging its strong European presence.

Qiagen is known for its sample preparation kits and automation systems like QIAsymphony and QIAcube, particularly suited for genomic and molecular biobanking. Stemcell Technologies supports regenerative medicine and stem cell biobanking with advanced cell culture tools and reagents, particularly in North America and Europe. PromoCell GmbH, while more niche, contributes through its high-quality human primary cells and cryopreserved samples used in research biobanks across Europe. Together, these players represent the technological and regional diversity driving innovation and adoption in the biobanking product and service landscape.

Key Biobanks Company Insights

Some of the key players operating in the market are adopting various organic & inorganic strategies, such as collaborations with biobanking service providers and technological innovation to advance their product offerings in the biobanking industry.

Recent Developments

• In July 2025, the German Biobank Node (GBN) will become part of the Network of University Medicine (NUM). This integration aligns with the recent approval of NUM’s new funding phase (NUM 3.0) by the Federal Ministry of Education and Research (BMBF) last week.

• In May 2024, EIT Health introduced a new Biobanks and Health Data Portal designed to enhance collaboration and promote the broader use of biobanks.

• In December 2023, Charles River Laboratories International, Inc. announced an agreement with CELLphenomics. The CELLphenomics biobank has over 500 in vitro models from around 20 tumor entities. It offers one of the largest complex in vitro models of rare and ultra-rare tumors like thymomas or sarcomas.

• In October 2023, AstraZeneca research announced unique relationships between rare changes in plasma proteins and genes that could enhance drug discovery with data from more than 50,000 UK Biobank participants.

• In July 2023, Tecan announced the launch of Phase Separator. It has several applications in biobanking and liquid biopsy and is expected to benefit proteomics, genomics, and across numerous disease areas, from neurodegenerative and oncology diseases to metabolic disorders.

Biobanks Market